Select region:

Clinical trials located in

Łódź

Łódź city is located in Poland. Currently, 20 clinical trials are being conducted in this city.

Łódź, Poland’s third-largest city, boasts a unique blend of industrial heritage and vibrant cultural life. Established in the 14th century, it flourished as a textile manufacturing hub in the 19th century, earning the nickname “Polish Manchester.” The city’s rich history is reflected in its eclectic architecture, from grandiose factories and workers’ housing to the opulent residences of industrial magnates along Piotrkowska Street, one of Europe’s longest commercial thoroughfares. Łódź is also renowned for its contributions to cinema, home to the prestigious National Film School, which has nurtured many acclaimed filmmakers.

  • CT-EU-00112165

    Exploring the safety and effectiveness of somapacitan for growth in children

    The study is focused on evaluating the safety and effectiveness of somapacitan, a new growth hormone treatment. This treatment, given once a week through an injection, aims to assist children who were born small for their gestational age or have been diagnosed with Turner syndrome, Noonan syndrome, or idiopathic short stature. Over a three-year period, the study will monitor for any adverse events or side effects, particularly observing how somapacitan impacts children with these specific  conditions. Participants will receive thorough training from the study team on administering the medication at home. This research is vital for potentially improving treatment and quality of life for children facing growth challenges, emphasizing participant safety and well-being throughout the study process.

    NetherlandsPolandSpain
  • Sparsentan Treatment Study for Children with Kidney Diseases

    We are excited to introduce a clinical trial focused on the study of Sparsentan treatment in children and adolescents with certain types of kidney diseases that lead to protein loss in urine, known as proteinuric glomerular diseases. This includes conditions like Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), IgA Vasculitis (IgAV), and Alport Syndrome (AS).

    The main goal of this study is to understand how safe, effective, and tolerable Sparsentan is when given as an oral suspension or tablet. We are particularly interested in seeing how this treatment can change the levels of protein in the urine over a period of 108 weeks.

    This study is designed as a Phase 2, Open-Label, Single-Arm trial, meaning all participants will receive the treatment, and there will not be a comparison group receiving a placebo. We are looking to enroll approximately 67 pediatric subjects, aged 1 year to less than 18 years, who have been diagnosed with one of the specified conditions. The study is divided into three populations based on the specific disease and age groups, with different dosages of Sparsentan being tested across these groups.

    The safety of the participants will be closely monitored throughout the study, with a special focus on any treatment-emergent adverse events, serious adverse events, and any adverse events that may lead to discontinuation of the treatment. Additionally, we will measure the change in the urine protein/creatinine ratio (UP/C) from the start of the study to week 108 to assess the effectiveness of Sparsentan in reducing proteinuria.

    This study represents an important step towards finding a potentially effective treatment for children and adolescents suffering from these challenging kidney diseases. If you or your child are dealing with one of these conditions and are interested in participating, we encourage you to consider this unique opportunity.

    GermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    AustriaBelgiumCzechiaDenmarkFranceHungaryItalyNorwayPolandSpainSwedenUnited Kingdom
  • Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

    BelgiumGermanyPolandSpain
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    BelgiumCzechiaFranceGreeceHungaryNetherlandsPolandSpainUnited Kingdom
  • Study on luspatercept treatment for Myelodysplastic Syndrome

    This study is looking into a medication named Luspatercept and how safe and effective it is for people who have a blood condition known as lower-risk Myelodysplastic Syndrome, or LR-MDS for short. These individuals often need transfusions or have their blood refreshed with new, healthy red blood cells. The drug will be given at its highest approved dose to see what effect it has. This is being done in a controlled and careful way to make sure everything is safe for the participants in the study. People who are taking part in this study have been identified as having a very low to medium risk according to the International Prognostic Scoring System (IPSS-R). This means their disease isnt considered high-risk, which makes them suitable candidates for this research. The study is open-label, meaning everybody knows what is in the drug they are getting.

    BelgiumCzechiaFranceGermanyItalyPolandSpain
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    AustriaBelgiumFranceGermanyItalyNetherlandsNorwayPolandPortugalSlovakiaSpainUnited Kingdom
  • Testing new medicine for resistant high blood pressure

    In this 20-week trial, the effectiveness, safety, and optimal dosage of a medication known as XXB750 are being evaluated in individuals with resistant high blood pressure (resistant hypertension). This condition persists despite the use of three different blood pressure medications. XXB750 will be administered through subcutaneous injections, and its efficacy will be compared to a placebo. A 2-week preparation period precedes the trial, during which participants receive three doses of the actual trial medicine and one dose as part of the preparation. Following the trial, participants will be monitored for an additional 8 weeks without receiving any trial medicine during this period. The primary focus is on assessing whether XXB750 can effectively reduce blood pressure when measured over a 24-hour period.

    AustriaBulgariaCzechiaFranceGermanyItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Study investigating new medicine for advanced metastatic breast cancer

    A clinical study is investigating the impact and safety of a new medicine named ARV-471 (Vepdegrestrant), contrasting its effects with an already-used drug called fulvestrant (FUL). This research targets individuals suffering from advanced metastatic breast cancer, a disease that often spreads to various parts of the body and is challenging to control. ARV-471 will be given to half of the participants, with the other half receiving fulvestrant. The effects of both will be monitored over time. ARV-471 is consumed by mouth, while FUL is administered through injections.

    BelgiumBulgariaCzechiaFinlandFranceGermanyGreeceHungaryItalyNorwayPolandSlovakiaSpainSwedenUnited Kingdom
  • Evaluating datopotamab deruxtecan & pembrolizumab for advanced lung cancer

    This study compares two treatments for people with a type of lung cancer called ‘non-small cell lung cancer’ that has spread to other parts of the body. It tests whether combining a drug called datopotamab deruxtecan (Dato-DXd) with pembrolizumab works better than using pembrolizumab alone. Aimed at patients with non-small cell lung cancer (NSCLC) who haven’t had previous systemic therapy, it’s especially for those with high PD-L1 tumor expression.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Testing safety and effects of telisotuzumab and docetaxel in Lung Cancer patients

    This study is for adults who have been treated before for a type of lung cancer called non-small cell lung cancer (NSCLC). The aim is to see if a new drug, called telisotuzumab vedotin, works better and is as safe as a common drug called docetaxel. In this study, cancer activity and any side-effects will be observed closely. The treatment will be given by a drip into a vein.The researchers will randomly decide whether each participant will get telisotuzumab vedotin or docetaxel, with an equal chance of getting either drug. While in the study, each person will have regular hospital or clinic visits to check how they are doing with tests and questionnaires.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Macitentan and selexipag in ongoing pulmonary hypertension care

    This study is for people with a lung disease called pulmonary hypertension (PH) who have taken part in a previous study and are receiving specific treatment. The main goal of the study is to enable these people to continue treatment even after the previous study has ended. The study involves monotherapy with Macitentan or Selexipag and a combination of Macitentan and Tadalafil at fixed doses. All of these drugs are administered orally. The aim of the study is to check how safe the treatment is when used long-term. Will be monitored if any adverse events occur. If this leads to discontinuation of treatment, this will be reported.

    BelgiumBulgariaPoland
  • Comparison of drug combinations in the treatment of advanced lung cancer

    This trial studies a first-line treatment involving Dato-DXd plus pembrolizumab compared to pembrolizumab alone in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations. The goal is to evaluate the effectiveness and safety of this combined strategy. Target volunteers must not have received any treatments for their advanced or metastatic NSCLC. Participation includes receiving either the combined treatment or pembrolizumab alone. Regular health checks will monitor if any changes or adverse events occur during the trial.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    AustriaBelgiumCzechiaFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Examining new drug combo vs. standard treatment with pembrolizumab for advanced lung cancer

    This trial is examining if a combination of two medications, Dato-DXd and pembrolizumab, could be superior to using pembrolizumab alone in treating a type of lung cancer known as metastatic non-small cell lung cancer (NSCLC). Participants will include those who have advanced or spread NSCLC and haven’t had systemic treatment for it. The team will be comparing whether the combination treatment can help patients live longer or keep the cancer from growing for a longer period. One group of participants will get pembrolizumab on its own, while another will get both Dato-DXd and pembrolizumab. An important part of the study will assess how the treatment affects the patient’s symptoms and quality of life.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Study on Aticaprant’s safety and effects as an adjunctive therapy for major depressive disorder

    This trial is for adults and elders who are struggling with major depressive disorder (MDD). The trial involves a medicine called aticaprant, and this is supposed to be taken alongside what they are already using to handle their depression (SSRI or SNRI drugs). The study aims to determine the long-term safety and efficacy of aticaprant. To achieve this, close monitoring of adverse events, which includes negative reactions or changes in patients’ health, is crucial. Physical health indicators, such as weight, core body temperature, heart rate, and blood pressure, will be assessed to understand the potential impact of aticaprant. Additionally, the study will evaluate patients’ thoughts on suicide, any discernible changes in their sexual health, and their overall mood.

    BelgiumBulgariaCzechiaFranceHungaryItalyPolandSlovakiaSpainSweden
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    BelgiumBulgariaDenmarkItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Examining new drug efficiency in avoiding blood clots post knee surgery

    This study is trying to find out how good a medicine named REGN9933 is at preventing blood clots after a person has a single knee replacement. We compare how it works with another medicine called enoxaparin. The main goal of the study is to see if REGN9933 is better at stopping venous clotting after this surgery. The trial will be focused on checking on the chance of bleeding happening after the operation, and if REGN9933 is safe and easy to tolerate for people having knee replacement. The trial will show the new drug’s ability to prevent dangerous clots, and its impact on deep venous thrombosis, which is a clot deep within a vein. Also, it’s essential to understand how it’s absorbed, and how it affects natural clotting mechanisms in the human body and the immune response over time. The study will compare REGN9933 with enoxaparin and another medicine named apixaban.

    BelgiumBulgariaHungaryPoland
  • Comparing the effectiveness of two treatments for severe nasal polyps and asthma

    This study is looking at two medications, called Dupilumab and Omalizumab, to see how well they work in people who have severe nose and sinus problems alongside asthma. The main goal is to see if Dupilumab is better at shrinking nasal polyps (small growths in the nose) and improving the sense of smell. Other goals include seeing if Dupilumab can improve symptoms, lung function, and overall health-related quality of life better than Omalizumab. The study also aims to understand how these drugs affect the severity of the disease and asthma control, and their safety. To assess all these, doctors will use various tests, like measuring the size of nasal polyps, testing the ability to smell, and how well one’s lungs are working. Participants in the study will be involved for 38 weeks.

    BelgiumCzechiaDenmarkFinlandFranceGermanyHungaryItalyPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    BelgiumFranceGermanyItalyNetherlandsPolandSpain

See more clinical trials in other cities in Poland:

.